Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Cell Reports|May 7, 2020
The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi NetworkAlexandra Beilina, Luis Bonet-Ponce, Ravindran Kumaran, et al.
Annals of Neurology|November 23, 2006
Localization of LRRK2 to membranous and vesicular structures in mammalian brainSaskia Biskup, Darren J Moore, Fulvio Celsi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2009
PINK1-dependent recruitment of Parkin to mitochondria in mitophagyCristofol Vives-Bauza, Chun Zhou, Yong Huang, et al.
Nature Communications|June 9, 2016
Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1Frederick C Nucifora, Leslie G Nucifora, Chee-Hoe Ng, et al.
Neurobiology of Disease|July 6, 2019
Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrilsJoseph R Patterson, Megan F Duffy, Christopher J Kemp, et al.
Human Molecular Genetics|May 6, 2014
A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicityJulien Dusonchet, Hu Li, Maria Guillily, et al.
Human Molecular Genetics|July 27, 2013
LRRK2 secretion in exosomes is regulated by 14-3-3Kyle B Fraser, Mark S Moehle, João P L Daher, et al.
Journal of Parkinson'S Disease|May 23, 2022
Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase ActivityBelén Fernández, Vinita G Chittoor-Vinod, Jillian H Kluss, et al.
Plos One|April 16, 2011
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2David Ramonet, João Paulo L Daher, Brian M Lin, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
Pageof 9